BRIEF-Anaptys Announces Phase 2B Trial Of ANB032, A BTLA Agonist, Did Not Meet Endpoints

Reuters
11 Dec 2024
BRIEF-Anaptys Announces Phase 2B Trial Of ANB032, A BTLA Agonist, Did Not Meet Endpoints

Dec 11 (Reuters) - AnaptysBio ANAB.O:

  • ANAPTYS ANNOUNCES PHASE 2B TRIAL OF ANB032, A BTLA AGONIST, DID NOT MEET PRIMARY OR SECONDARY ENDPOINTS IN ATOPIC DERMATITIS

  • ANAPTYSBIO INC: ANTICIPATE TOP-LINE PHASE 2B DATA IN RHEUMATOID ARTHRITIS IN FEBRUARY 2025

  • ANAPTYSBIO INC - ANB032 AD TRIAL AND ALL FURTHER INVESTMENT WILL BE DISCONTINUED

  • ANAPTYSBIO INC - ANB032 WELL TOLERATED WITH NO SAFETY SIGNALS OBSERVED

  • ANAPTYSBIO INC - YEAR-END 2024 CASH ABOUT $415 MILLION

Source text: ID:nGNXbd61Yl

Further company coverage: ANAB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10